BioWorld

April 8, 2004

View Archived Issues

Indevus Gains Pliva As Sanctura Partner Via Potential $215M Deal

As Indevus Pharmaceuticals Inc.'s overactive bladder product nears the market, the company laid out a U.S. commercialization plan with Zagreb, Croatia-based Pliva d.d. (BioWorld Today) Read More

Favrille's Series C Raises $44M For FavId Pivotal Phase III Trial

Read More

Pfizer Deal Propelled Eyetech From Frustration To Triumph

Read More

ViaCell Again Considering IPO, Now Anticipating $92M Offering

Read More

Other News To Note

Read More